Vivo Capital LLC lifted its holdings in Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) by 22.6% during the third quarter, Holdings Channel reports. The institutional investor owned 2,328,475 shares of the biotechnology company’s stock after buying an additional 428,475 shares during the period. Arrowhead Pharmaceuticals makes up about 4.5% of Vivo Capital LLC’s portfolio, making the stock its 6th biggest holding. Vivo Capital LLC’s holdings in Arrowhead Pharmaceuticals were worth $44,637,000 at the end of the most recent quarter.
Several other institutional investors have also bought and sold shares of ARWR. RTW Investments LP increased its holdings in shares of Arrowhead Pharmaceuticals by 184.6% in the 2nd quarter. RTW Investments LP now owns 8,299,542 shares of the biotechnology company’s stock worth $112,874,000 after buying an additional 5,382,981 shares during the last quarter. BlackRock Inc. grew its holdings in Arrowhead Pharmaceuticals by 108.1% during the 2nd quarter. BlackRock Inc. now owns 7,083,926 shares of the biotechnology company’s stock valued at $96,342,000 after purchasing an additional 3,679,986 shares during the last quarter. FMR LLC bought a new position in Arrowhead Pharmaceuticals in the 3rd quarter worth about $37,922,000. Northern Trust Corp grew its stake in Arrowhead Pharmaceuticals by 380.1% in the 2nd quarter. Northern Trust Corp now owns 1,063,499 shares of the biotechnology company’s stock worth $14,464,000 after acquiring an additional 841,982 shares in the last quarter. Finally, First Manhattan Co. lifted its position in shares of Arrowhead Pharmaceuticals by 11.6% in the 3rd quarter. First Manhattan Co. now owns 5,053,925 shares of the biotechnology company’s stock worth $96,883,000 after purchasing an additional 523,675 shares during the period. Hedge funds and other institutional investors own 63.33% of the company’s stock.
A number of research firms have issued reports on ARWR. William Blair reaffirmed an “outperform” rating on shares of Arrowhead Pharmaceuticals in a report on Wednesday, October 17th. Chardan Capital set a $25.00 price target on shares of Arrowhead Pharmaceuticals and gave the company a “buy” rating in a research report on Sunday, October 14th. Cantor Fitzgerald restated a “buy” rating and set a $24.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Thursday, October 11th. BidaskClub downgraded shares of Arrowhead Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, October 6th. Finally, Piper Jaffray Companies reissued an “overweight” rating and issued a $25.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Thursday, October 4th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $21.45.
In other news, VP Peter Brian Leone sold 131,137 shares of the business’s stock in a transaction that occurred on Friday, October 19th. The shares were sold at an average price of $13.49, for a total transaction of $1,769,038.13. Following the completion of the sale, the vice president now owns 160,000 shares in the company, valued at approximately $2,158,400. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Douglas B. Given sold 3,000 shares of the business’s stock in a transaction that occurred on Friday, November 23rd. The stock was sold at an average price of $12.74, for a total transaction of $38,220.00. The disclosure for this sale can be found here. Insiders have sold a total of 425,471 shares of company stock valued at $6,232,194 in the last quarter. 4.60% of the stock is currently owned by company insiders.
Arrowhead Pharmaceuticals Profile
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. Its medicines include ARO-HBV, a Phase I/II subcutaneous ribonucleic acid interference(RNAi) therapy candidate that is used for the treatment of chronic hepatitis B viral infection; ARO-AAT for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; ARO-APOC3 and ARO-ANG3 to treat hypertriglyceridemia; ARO-Lung1 for the treatment of an undisclosed pulmonary target; ARO-HIF2 to treat renal cell carcinoma; ARO-F12 for hereditary angioedema and thromboembolic disorders; and ARO-AMG1 for the treatment of an undisclosed genetically validated cardiovascular target.
Featured Story: How to interpret a stock’s beta number
Want to see what other hedge funds are holding ARWR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR).
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.